MTI reports strong FY2025 growth, mixed FY2026 outlook

MTI Ltd. announced a robust financial performance for FY2025, with net sales reaching ¥29,910 million, an 8.1% year-over-year increase. Operating income surged by 23.1% to ¥2,946 million, and profit attributable to owners of parent saw a substantial 44.0% rise to ¥3,404 million. This growth was primarily driven by strong performance in its healthcare and school DX businesses. The company also highlighted significant traction in its cloud-based medication history service, which expanded to 3,811 pharmacies, and its full cloud-based school affairs support system, now adopted by 1,067 schools, covering 50% of private middle and high schools.

For FY2026, MTI forecasts continued growth with net sales projected at ¥31,000 million, a 3.6% increase. Operating income is expected to range between ¥3,100 million and ¥3,500 million, representing a 5.2% to 18.8% increase. However, profit attributable to owners of parent is anticipated to decline to ¥1,770 million–¥2,050 million, a decrease of 39.8% to 48.0%, primarily due to a reduction in extraordinary gains such as consumption tax refunds.

The company plans to focus on sales and profit growth in its healthcare and school DX businesses, alongside securing profit in its content business, driven by expanding high-growth content and steady growth in corporate DX. MTI also announced a dividend forecast of ¥10 for both interim and year-end dividends for FY2026, totaling ¥20 annually.